--------------------------------------------------------------------------------------------------------------------- Roche 2004

\*{combination, financial report, integrated part, Annual Report, first time, representing, Roche Group, inclusion, majority, holdings, Chugai, Genentech, OTC business, non-prescription medicines}

\*{publishing, reports, testifies, deep conviction, sustainability, business, marketing tool}

\*{profit- oriented company}

\*{economic objective, achieved, basis of short-term profit maximization}

\*{long- term, sustainable point of view}

\*{employee, company, contribute, sustainable creation of value, area}

\*{invest, development of innovative solutions, unsolved health problems, interests, parties involved, responsibility, direct field of activity}

\*{central part, long-term strategy, unite, entrepreneurial responsibility, innovation, interests of health}

\*{visible sign, success, efforts, increase, transparency, actions, sustainable terms, leading sustainability indexes, Dow Jones Sustainability World Index (DJSI World), Dow Jones STOXX Sustainability Index (DJSI STOXX)}

\*{preceded, examination, economic, social, environmental performance}

\*{certification, independent party, objective criteria, leading company, successful, orienting, principles, sustainable development}

\*{success, aim, maintain, high standards, benchmark}

\*{scientific commitment, research and development, health solutions, economic risk, contribution, sustainability}

\*{invest, funds, efficient solutions, unresolved health problems}

\*{invested, research and development}

\*{opening, research centre, Shanghai, innovation-oriented company}

\*{creating, jobs, qualified scientists, country}

\*{Transparency, clinical research, new substances, medicines}

\*{ethical duty, publish, results, clinical studies, significance, science, medicine}

\*{support, new industry-wide solution, ongoing studies, results of finished studies recorded, independent neutral office, available, public}

\*{success, Pharmaceuticals, Diagnostics Divisions, products, services, markets, create, new jobs, aim, qualified people}

\*{orientation, employment policy, sustainable creation of value}

\*{objectives, senior management, career, succession, introduced, transparent, motivating performance culture, creates, employees, company, develop}

\*{efforts, sustainable thinking, action, company, employees, successful}

\*{Sustainability, duty, employee, practiced, business area, activity}

\*{employee, place of work, contributes, sustainable value creation, future}

\*{overwhelming success, worldwide competition, ecological ideas, ECOmpetition, creativity, willingness, participate, employees}

\*{approach, challenging goals optimistically}

\*{Corporate Sustainability Committee, sustainable thinking}

\*{responsible, preparing, corporate guidelines, apply, coordination}

\*{new guidelines, relationship, external business partners, supply chain, approved, Executive Committee}

\*{responsibility, business activities, strictest sense, definition}

\*{commitment, Least Developed countries, UN, practice, extended, patent, pricing policy, introduced}

\*{cooperation, local partners, areas, inadequate medical care, success, South Africans, rural areas, benefit, Phelophepa health train}

\*{tsunami disaster, Asia, action, swift, careful assessment, general managers, together, local authorities, international aid organisations}

\*{immediate medical and financial aid, country affiliates, reserved, available stocks of antibiotics, available, international aid organization}

\*{treat, individuals, affected areas}

\*{young scientists, scientific institutions, opportunities, partner foundations}

\*{Roche Research Foundation, support, scientists, projects}

\*{developed, special tradition, work together, contemporary art and culture}

\*{Projects, Tinguely Museum, Basel, commission, composer, Roche Commissions, illustrate, promoting, innovation, willingness, support, unconventional, challenging, excellence, activities, attractions, short-term popularity}

\*{figures, safety, health, environmental protection, positive, emissions of harmful substances, consumption, resources, reduced}

\*{accidents, damaging events, impact, people, environment}

\*{achievement, industrial company}

\*{Regular reporting, sustainability, update of information, review, status quo, interests, broader public}

\*{Sustainability Report, transparency, progress}

\*{sustainability, demanding process, addition, awareness, employees, working collaboration, stakeholder groups, regulatory authorities, constructive, participation, suppliers, willingness, healthcare providers, dialogue, trust, loyalty of doctors, patients, products, services}

\*{shareholders, holders, non-voting equity securities, long-term strategy}

--------------------------------------------------------------------------------------------------------------------- Roche 2005

\*{company, outstanding, innovative Roche medicines, diagnostics, advance, fight, serious diseases}

\*{Operationally, financially, Group, strong results, substantial market share gains, improvement, operating profitability}

\*{General Meeting, Shareholders, Board of Directors, dividend, increase, non-voting equity security}

\*{approved, dividend, increase}

\*{Sales, local currencies, exceeded}

\*{Pharmaceuticals Division, increase}

\*{sales, average market growth rate}

\*{Diagnostics Division, leadership position, difficult market, performance goals}

\*{Group operating profit, exceptional items, rise, record high}

\*{net income, figure, income, recorded, divested consumer health business}

\*{strong earnings performance, invest, research and development, expand, production base}

\*{Group expenditure, research and development, world’s most research-intensive companies}

\*{investing, new biotech manufacturing facilities, rising demand, products}

\*{excellent financial health}

\*{strengthened, balance sheet, increased}

\*{equity, total assets, risen steadily}

\*{increased financial strength, strategic flexibility, selectively expand, core pharmaceuticals, diagnostics businesses}

\*{Standard & Poor’s and Moody’s, awarded, Roche credit ratings, second highest ratings, agencies}

\*{Pharmaceuticals Division}

\*{expiry, US patent, Rocephin, top-selling medicine, division increased, sales}

\*{medicines, sales, cases}

\*{division’s operating profit margin, items, improvement, advancing}

\*{oncology portfolio, key driver, superb results}

\*{healthcare company, five medicines, cancer, market, increase, patient survival}

\*{space, new generation, less toxic anticancer medicines, global market leader, oncology}

\*{reinforced. Leadership, sales growth}

\*{innovative new additions, oncology portfolio, Avastin, colorectal cancer, Tarceva, lung cancer, established}

\*{New Roche medicines, launched, therapeutic areas, approvals, new indications, increase, prescriptions, existing drugs}

\*{captured, attention of health professionals, public, new clinical data}

\*{data, Herceptin, difference, early-stage treatment, aggressive breast cancers}

\*{clinical trials, adding, Herceptin, standard therapy, risk of cancer recurrence, compared, standard therapy}

\*{trial of MabThera/ Rituxan, lymphoma patients, maintenance therapy, drug, increase, survival, disease}

\*{claim}

\*{drug research, development, drug, approved, indication}

\*{development of anticancer drugs, new level, core missions, global research organization}

\*{progress, projects, develop, novel biotherapeutics, rheumatoid arthritis, common disease, progressive inflammation, progressive destruction, joints}

\*{clinical trial data, top-selling anticancer medicine, MabThera/Rituxan, new approach, treating, rheumatoid arthritis}

\*{product, developed, Chugai subdivision, clinical trials, joint, damage, improve, disease’s painful, disabling symptoms}

\*{chances, disease area}

\*{threat, potential flu pandemic, challenges}

\*{increased global demand, leading influenza drug, Tamiflu}

\*{initiated, scale-up, production capacity, risk, pricing policy, discounts, drug, pandemic use, Tamiflu, World Health Organization, response, stockpile, epicenter, potential pandemic, establish, regional stockpiles, drug}

\*{sub-licences, production, drug, pandemic use, companies, additional manufacturing support}

\*{Roche Diagnostics, focused, launching, new products, diabetes management}

\*{division, expand, markets, DNA sequencing}

\*{market conditions, difficult, Roche Diagnostics, leading market, position, sales, advancing, local currencies}

\*{division’s immune-diagnostics, molecular diagnostics portfolios, growth drivers}

\*{Roche Diagnostics, operating profit, exceptional items}

\*{Divisional profitability, industry, decrease, operating profit margin}

\*{pricing pressures, production, start-up costs, costs, new products, launch, decline}

\*{global market leader, obligation, supply, advanced diagnostics, contribution, effective, cost-efficient patient care}

\*{new generation, Accu-Chek products, improved diabetes management, launch, perfect case}

\*{European, US launches, AmpliChip, product, personalised medicine}

\*{DNA microarray test, doctors, patient’s ability, metabolise, drugs, patient’s genetic profile, information, drug selection, dosing decisions}

\*{DNA microarray tests, cancer screening, late-stage development}

\*{Group’s strong performance, created, new jobs, employees}

\*{opportunity, people, dedication, professionalism}

\*{value, create, invest, developing innovative solutions, areas of unmet medical need}

\*{patient care, more effective, more cost-efficient, clinically differentiated, medicines, diagnostics, ease, pressure, healthcare budgets}

\*{socially, environmentally sustainable development, delivering long-term benefits, patients}

\*{reselected, inclusion, Dow Jones Sustainability Indexes, FTSE4Good Index, ranked second, pharmaceutical industry category}

\*{sustainability efforts}

\*{respected publications, best companies}

\*{responsible corporate citizen, healthcare innovator}

\*{availability of Tamiflu, event, pandemic, responsibilities, company}

\*{high standards, policies, practices, transparency, clinical research}

\*{disclose, negative and positive results, late-stage trials, publishing data, clinical trials}

\*{established, independently hosted, publicly accessible online, trial protocol registry, information}

\*{commitment, corporate social responsibility, extends, world’s least developed countries}

\*{few companies, research, HIV/AIDS, supplies, medicines, cost, patent rights, poorest developing countries}

\*{announced, technical expertise, manufacture, AIDS drug, saquinavir, manufacturers, Least Developed Countries, no cost}

\*{contribution, sustainability, developing, new and better solutions, unmet medical needs}

\*{viability, success, innovative company, business, socially, environmentally responsible way}

\*{outlook, very positive}

\*{portfolio, innovative products, create, value}

\*{expect, divisions, achieve, above-market sales growth, local currencies, target, core earnings per share, rise, Group sales}

--------------------------------------------------------------------------------------------------------------------- Roche 2006

\*{strong growth, outstanding financial performance}

\*{Group’s sales, rise, local currencies, record high}

\*{revenue increase, organic growth}

\*{Top-line growth, Pharmaceuticals Division, sales, advanced, market growth rate}

\*{Roche Diagnostics, leadership position, increasingly competitive market, new product, launches, continued growth, division’s business areas}

\*{Group’s earnings performance, improve}

\*{Operating profit, exceptional items, increased, local currencies}

\*{Group’s operating profit margin, increase}

\*{invest, divisions’ rich research and development pipelines, increase, spending, launch activities, construction, new biotech manufacturing facilities}

\*{Net financial income, up}

\*{Total net income, rise, highest profit ever recorded}

\*{Core Earnings per Share, rise}

\*{Board of Directors, dividend, increased, non-voting equity security}

\*{approval, Annual General Meeting of Shareholders, consecutive dividend, increase}

\*{Pharmaceuticals Division, Group’s excellent results}  
\*{sales, exceeded, increase, local currencies, market, growth}

\*{robust increase, sustained strong demand, cancer medicines, continued government, stockpiling, anti-influenza drug Tamiflu, sales of Bonviva/Boniva, osteoporosis}

\*{Oncology, transplantation, virology, leading therapeutic franchises}

\*{sales, cancer medicines, division’s total revenues}

\*{Pharmaceuticals Division’s operating profit, exceptional items, exceed, operating profit margin, rise}

\*{Diagnostics Division, sales, increase, local currencies}

\*{slow start, sales growth, accelerated, market growth rate, roll-out, new products}

\*{division’s Centralized Diagnostics business, immunodiagnostics portfolio, contributor, growth}

\*{new portfolio, Accu-Chek blood glucose, monitoring products, market, expect, Roche Diabetes Care, return, above-market growth}

\*{Divisional operating profit, exceptional items, declined, local currencies}

\*{decrease, higher costs, new product, launches, ongoing pricing pressure, division’s markets}

\*{Operating profit, impacted, impairment charges, intangible assets, Disetronic acquisition}

\*{Roche’s strategy, focused, prescription medicines, modern diagnostics}  
\*{increased financial strength, resources, targeted business-building, investments, core businesses}

\*{Developing, healthcare innovations, products, services, representing, real advances, fight, serious diseases, mission, change}

\*{research and development activities, aim, extending patients’ lives, improving, health, quality of life}

\*{pursuit, objectives}

\*{R&D expenditure, Pharmaceuticals Division, sales}

\*{absolute figures, total R&D expenditure, rise, research-intensive companies, industry}

\*{plan, intensify, cooperation, Pharmaceuticals, Diagnostics Divisions, major therapeutic areas, deliver, products, needs, specific patient populations}

\*{benefits, precise diagnoses, targeted treatments, oncology}

\*{Tighter cross-divisional linkages, research and development, marketing organisations, strengthen, ability, future therapeutics, diagnostics}

\*{reselected, inclusion, Dow Jones Sustainability Indexes}

\*{recognition, efforts, balance, corporate responsibility, business objectives, core mission, innovate healthcare}

\*{sustainability, integral part, business model, operations, fosters, innovation, minimizes, business risks, creates, value, stakeholders}

\*{final analysis, Roche’s people, prosperous, innovative, company}

\*{dedication, professionalism, products, services, market, difference, patients’ lives}

\*{strong businesses, create, new jobs}

\*{employees, increased}

\*{opportunity, employees, job, tough and challenging marketplace}

\*{awards, received, outstanding company}

\*{innovation, medical progress, access, quality healthcare, unsustainable}

\*{raise, awareness, pricing, patent protection, industry’s ability, innovate}  
\*{engage, policymakers, public, issues}

\*{healthcare market, opportunities, enormous challenges}

\*{opportunities, tackle, challenges, confidence, position of strength}

\*{strategy, focused innovation, portfolio, new products, equipped, sustained growth}

\*{Pharmaceuticals Division, sales, grow, double-digit rates, local currencies, above-market sales growth, divisions}

\*{aim, Core EPS, increase, Group sales}

--------------------------------------------------------------------------------------------------------------------- Roche 2007

\*{company, outstanding results, tougher market conditions}

\*{sales, increased, double-digits, advancing}

\*{increase, sales revenues, achieved}

\*{Pharmaceuticals Division, main growth driver}

\*{sales, grew, global pharmaceuticals market}

\*{Diagnostics Division, position, global market leader, diagnostics, divisional sales, increasing, market}

\*{Revenue growth, outpaced costs, improvement, Group’s earnings performance}

\*{Board of Directors, propose, dividend, increased, non-voting equity security}

\*{Subject, approval, next Annual General Meeting of Shareholders, consecutive annual dividend, increase}

\*{research and development, expenses, increased, grew, sales, costs increased, sales, result, programmes, increase, productivity}

\*{positive impact, profitability}

\*{operating profit, rise, corresponding profit margin, advanced}

\*{Group’s strong operating performance, combined, lower effective tax rate, boosted net income}

\*{record income, exceptional items}

\*{equity ratio, balance sheet, strengthen}

\*{operating profit, operating profit margin, doubled}

\*{growth, Core Earnings per Share, averaged, growth}

\*{achieved, Core EPS growth}

\*{positive development, portfolio, products, driving, business success}

\*{Pharmaceuticals Division, medicines, generate annual revenues, produce, annual sales}

\*{Diagnostics Division, product lines, generate, revenues}

\*{products, patent expiry}

\*{strengthen, portfolio, launching, new medicines, Actemra, gain, additional new indications, leading cancer medicines}

\*{enhanced, ability, innovate, main therapeutic areas of interest, oncology, virology, inflammatory diseases, metabolic diseases, diseases of central nervous system}

\*{areas, encompasses, activities, drug discovery, clinical development, strategic marketing}

\*{streamlining decision-making processes, new approach, research activities, marketed products, efficiently, effectively}

\*{reinforced, presence, opening, clinical development centre, pharmaceuticals}

\*{pharmaceutical operations, key emerging market, entire value chain, research, clinical development, manufacturing, marketing, distribution}

\*{Construction work, new biotech manufacturing facilities, buildings, completed, schedule}

\*{facilities, total investment, growing demand, cancer medicines, demand, future, medicines, medium, long term}

\*{invest, new technologies}

\*{entering, alliances, leading companies, pioneering, new fields, DNA sequencing, microarrays, therapeutic, antibodies, RNAi therapeutics}

\*{Transactions, open, developing new, better diagnostic tests, treatments, complex diseases}

\*{signed, merger agreement, US-based diagnostics company, Ventana Medical Systems}

\*{acquisition, move, fast-growing market, tissue-based diagnostics}

\*{Acquiring, Ventana, contribute, develop, commercialise, personalised healthcare solutions, oncology}

\*{strategy, focused, innovating healthcare}

\*{medium, long term, global research network, strengths, biotechnology, leadership, developer of diagnostic products, sources of competitive advantage, changing healthcare market}

\*{combining, balancing, pursuit of innovation, corporate social responsibility}

\*{recognition, selected, inclusion, Dow Jones STOXX, World Sustainability Indexes}

\*{progress, specifically, protecting, environment, honoured, award, reducing, carbon dioxide emissions, sales}

\*{indication, integral sustainability, environmental protection, business, energy use, sales revenue}

\*{sustainable policies, practices, minimize, business risks, create value, promote innovation}

\*{Board of Directors, voted, split, positions, Chairman of the Board, Chief Executive Officer}  
\*{Annual General Meeting, CEO, concentrate, duties, Chairman}

\*{designating, Roche’s next CEO, Board, selected, individual, impressive track record}

\*{broad international experience, new role, gained, variety of divisional, corporate-level assignments, strategy of innovation}

\*{succeeded, CEO of Roche Diagnostics}

\*{experience, diagnostics business, instrumental, establishing, leader, Europe’s *in vitro* diagnostics market}

\*{join, Roche’s Corporate Executive Committee, Group’s most senior human resources executive, serve, CEC}

\*{fill, key positions, people, organization}

\*{assured, Chairman, Board, Corporate Executive Committee, achieve, Roche’s ambitious goals, world’s leading healthcare groups}

\*{opportunity, employees, contributions}

\*{professionalism, dedication, successful company}

\*{challenges, opportunities, healthcare industry, confidence, position of strength}

\*{achieve, high single-digit increase, Group sales, above-market sales growth, divisions}

\*{government, corporate, stock-piling orders, Tamiflu, pandemic use}

\*{orders, anticipate, decrease, pandemic Tamiflu sales}

\*{increase, investment, research and development, development projects, capture, full potential, strong pipeline}

\*{aim, Core EPS, high level}

--------------------------------------------------------------------------------------------------------------------- Roche 2008

\*{global financial, economic crisis}

\*{company, perform strongly, achievements}

\*{Pharmaceuticals, Diagnostics Divisions’ sales, grow, respective markets}

\*{Group sales, rise, local currencies, excluding, pandemic Tamiflu sales, expect, declined}

\*{pandemic Tamiflu, sales, increased}

\*{operating profit, increased, increased, research and development spending, promising projects, strong development pipeline}

\*{Net income, down, record high, appreciation, currencies, lower financial income}

\*{Core Earnings per Share, constant exchange rates, higher}

\*{latest strong results, Board of Directors, propose, dividend, increased, non-voting equity security}

\*{Subject, approval, next Annual General Meeting of Shareholders, consecutive annual dividend, increase}

\*{today’s turbulent economic climate, focused, developing products, improve, treatment options available, patients}

\*{strategy, yielded, advances, diagnosis, treatment of cancer}

\*{large-scale clinical trials, conducting, Avastin, first targeted cancer medicine, halts, development of new blood vessels, tumours}

\*{trials, investments of time and money, longer and better life, patients, suffering, cancers}

\*{Ventana, U S-based leader, tissue diagnostics, acquired, 3.8 billion Swiss francs, perform}

\*{access, tissue-based diagnostic tests, technologies, develop, personalised treatments, cancer}

\*{progress, developing, biological medicines, treatment of rheumatoid arthritis (RA), autoimmune disease, affects, people}

\*{novel medicine, Actemra/ RoActemra, approved, treatment of RA, Japan, European Union}

\*{MabThera/ Rituxan, leading cancer medicine, benefit, RA patients}

\*{Data, clinical trial, MabThera/ Rituxan, prevent, structural damage, joints, patients, early RA}

\*{projects, entered, final stage of clinical development, promising new molecules, treatment, breast cancer, diabetes, cardiovascular risk reduction}

\*{intention, purchase, outstanding shares of Genentech, company, stake}

\*{completing, transaction}

\*{Genentech, Roche Group, enhance, Group’s ability, innovative, long term}

\*{preserve, Genentech’s unique innovation culture}

\*{encourage, promote, diversity, research approaches, create, medical progress}

\*{existing research networks, technologies, expertise, pharmaceuticals, diagnostics businesses, shared across}

\*{leverage, scale, combined operations, US, improve, operational efficiency}

\*{position of strength, conviction, proposed transaction, best interests, companies’ employees, patients, shareholders}

\*{Roche’s Board of Directors, Corporate Executive Committee, transaction, goal, world’s leading healthcare company}

\*{operating, businesses, responsible, sustainable manner, respects, needs of all stakeholders}

\*{products, contribution, society, provide, benefits, patients, improving, people’s health, increasing, quality, length of life}

\*{recognize, responsibility, expand, global access, products}

\*{partnerships, collaboration, stakeholders}

\*{achieved, environmental goals, improving, energy efficiency, reducing, emissions of greenhouse gases}

\*{sustainable policies, business practices, create, long-term corporate value, support, innovation}

\*{recognition, efforts, selected, inclusion, Dow Jones World Sustainability Index}

\*{opportunity, employees, dedication, professionalism}

\*{efforts, Roche, world’s most successful companies}

\*{Recruiting, retaining, developing, talented people, tasks}

\*{unforeseen events, perform strongly}

\*{Pharmaceuticals, Diagnostics Division, full-year sales, grow, market, increases, mid-single-digit range, local currencies}

\*{invest, large-scale confirmatory clinical trials, long-term success}

\*{higher research and development costs, decrease, net financial income, aiming, Core Earnings per Share (Core EPS), constant exchange rates, high level}

\*{Genentech transaction, positive impact, Core EPS}

--------------------------------------------------------------------------------------------------------------------- Roche 2009

\*{sustained global financial, economic crisis, successful year}

\*{Sales, Pharmaceuticals, Diagnostics Division, grew}

\*{Group sales, increased, local currencies, driven, leading medicines, treat, patients, cancer, viral infections, age-related blindness, serious diseases}

\*{Sales, influenza medicine Tamiflu, contribute, revenue growth}

\*{Operating profit, exceptional items, grew, sales, advancing, local currencies}

\*{merger agreement, Genentech, finalization, transaction, complete, integration}

\*{combining, Roche, Genentech, increasing, operational efficiency, promoting, internal knowledge transfer}

\*{strengthening, innovative power, long term, patients, innovative medicines, research, quality}

\*{Excellent research, requirement, development of therapies, patients’ health, quality of life}

\*{concluding, Genentech integration, continue, systematically pursue, diverse research approaches, innovative healthcare solutions}

\*{creates, scope, creativity, increases, chances of devising sustainable medical, therapeutic progress}

\*{Genentech Research, Early Development, continue, function, independent unit}

\*{combining, activities, companies, areas of product development, production, sales, generated, increases, productivity}

\*{aim, achieve, pretax annual savings}

\*{operating, free cash flow, increased, negative currency effects}

\*{strong operating performance, Core Earnings per Share}

\*{exceptional costs, integration-related, operating profit, declined}

\*{Exceptional items, impacted, net income, declined}

\*{Excluding, exceptional items, net income, shareholders, increased}

\*{operating results, Annual General Meeting the Board of Directors, propose, increase, dividend, non-voting equity security}

\*{approval, consecutive annual dividend, increase}

\*{rapid spread of the pandemic A (H1N1) influenza virus, challenge, governments}

\*{supporting, World Health Organization (WHO), national governments, global efforts, fight, new virus}

\*{treatment courses of Tamiflu, donated, WHO’s regional, rapid-response stockpiles}

\*{sublicences, manufacturers, produce, generic oseltamivir, pandemic use, developing countries, local populations, areas, access to medication}

\*{initiated, Tamiflu Reserves Program, improve, Tamiflu access, developing countries}

\*{increased WHO pandemic threat level, network of manufacturing partners, scaled up, production, treatment courses, supply, packs}

\*{received, recognition, achievements, several areas}

\*{Dow Jones Sustainability Indexes, new ‘Super Sector Leader’, Healthcare, ranking, most sustainable healthcare company worldwide}

\*{Roche, Genentech, voted, ‘best employer’, countries}

\*{opportunity, employees, dedication, professionalism, challenging time}

\*{Scientific excellence, innovation, core pharma, diagnostics businesses, foundation, success}

\*{oncology, developing, new therapeutics, metabolic, autoimmune diseases, viral infections, disorders, central nervous system}

\*{world’s largest biotech company, promising R&D pipelines}

\*{new molecular entities, clinical testing, late stage development, standards, industry}

\*{compounds, entered, late phase development, potential new therapies, breast cancer, diabetes}

\*{published, early phase clinical trial data, targeted treatment, companion diagnostic, malignant melanoma patients, cancer cells, specific genetic mutation, malignant melanoma, deadliest form, skin cancer}

\*{new compound, effectively slowed, tumor progression, increased, patients’ quality of life}

\*{fight, cancer, untreatable}

\*{key achievements, Diagnostics Division, start, rollout, cobas, modular analyser series, large medical laboratories, launch, new products, Accu-Chek line of blood-glucose monitors, people, diabetes}

\*{CEO, Pharmaceuticals Division, CEO, Diagnostics Division, Head of Roche Group Research, Corporate Executive Committee,}

\*{contributions, success}

\*{generation of managers, healthy future, independent company}

\*{fulfilled, manner, profound conviction}

\*{contributed, strong market position, success}

\*{Board of Directors, Corporate Executive Committee, service, loyalty, relationship}

\*{industry knowledge, Board of Directors, appointing, Chairman of Genentech Board of Directors, Board of Directors of Roche Holding, Annual General Meeting}

\*{decided, re-election, Annual General Meeting}

\*{contributions, company}

\*{unforeseen events, sales, Pharmaceuticals Division, Group, Increase, mid-single-digit range, local currencies, Diagnostics Division, full-year sales, grow, market}

\*{aim, achieve, double-digit Core Earnings per Share growth, constant exchange rates}

\*{repaid, debt, raised, finance, Genentech transaction}

\*{Based, Group’s strong operating free cash flow, return, a net cash position}

\*{dividend policy}

--------------------------------------------------------------------------------------------------------------------- Roche 2010

\*{challenging year, pharmaceutical industry}

\*{Market conditions, tougher}

\*{financial crisis, high government budget deficits, pricing pressures, global health care sector}

\*{Europe, governments, cut, drug prices, healthcare reform, higher rebates, prescription drugs}

\*{regulatory front, hurdles, gaining, approval, new medicines, raised, increasing, cost of drug, development, delaying, access, innovative treatments}

\*{challenges, good full year results}

\*{market changes}

\*{US Food Drug Administration(FDA), rejected, application, approval, T-DM1, novel compound, improve, treatment of breast cancer}

\*{increase, clinical development costs, T-DM1, delay, promising, drug’s approval}

\*{FDA, announced, intention, withdraw approval of Avastin, combination, chemotherapy, treatment of metastatic HER2, negative breast cancer}

\*{withdrawal, not affect, US patients’ access, Avastin, approved, cancer indications, adversely impact, patients, serious disease}

\*{FDA, announcement, European Medicines Agency (EMA), confirmed, Avastin’s value, fight against, breast cancer}

\*{Europe women, advanced breast cancer, access, treatment option}

\*{monitoring developments, healthcare policy}

\*{innovative products, contribute, effective, cost efficient healthcare delivery, future, policymakers, health officials, costs of new medicines, innovation, benefits, patients}

\*{diseases, treated, medical progress, public good, deserves, political support}

\*{discuss, innovation, inherently risky}

\*{Pioneering, research and development, efforts, produce, breakthroughs, achieve, desired endpoints}

\*{Taspoglutide}

\*{suspended, late-stage development programme, new treatment, type 2 diabetes, late-stage of development, careful assessment, available safety, efficacy data}.

\*{research and development activities, yielded, strong and promising results}

\*{new molecular entities, late-stage development, targeted use, specific patient populations, companion diagnostic tests}

\*{progress, personalized healthcare, interplay, Pharmaceuticals and Diagnostics Divisions}

\*{developments, major strides, industry leader}

\*{sales, earnings targets}

\*{Excluding sales, influenza medicine, Tamiflu, down, sales, rise, local currencies}

\*{Net income, shareholders, strong increase, advancing, costs, ‘Operational Excellence’, programme}

\*{Core Earnings per Share, key indicator, underlying business, performance, increased, local currencies}

\*{company’s healthy cash flow, positive, outlook, Board of Directors, propose, dividend increase, non-voting equity, security}

\*{approval, Annual General Meeting(AGM), consecutive annual dividend, increase}

\*{Annual General Meeting, upcoming changes, Board of Directors}

\*{decided, not to stand for re-election}

\*{entire Board, dedicated service}

\*{long tenure, Board, runs, successful family company, contributions, growth, success}

\*{strengths, Board, expertise, growth markets, Eastern Europe, Middle East}

\*{intend, opportunity, strengthen, Board, nominating, additional independent directors}

\*{election, new members of Board}

\*{Annual General Meeting, propose, term of Board members, reduced}

\*{shareholders, influence, composition of Board, intervals, future}

\*{exceptional service, Corporate Executive Committee, retire}

\*{appointed, Chief of Financial Officer, deputy Head of Corporate Executive Committee}

\*{long career, key architects, successful development}

\*{opportunity, contribution, success}

\*{Board of Directors, appointed, succeed, Chief of financial Officer}

\*{join, member, Corporate Executive Committee}

\*{served, member, the executive board of Continental}

\*{member, executive board}

\*{company, achievements, areas}

\*{Dow Jones Sustainability Indexes, Supersector, Leader, healthcare, ranking, world’s most sustainable healthcare company}

\*{sustainable corporate policies, practices, create, long term value, promote, innovation}

\*{success, company, built, scientific excellence, benefits, patients}

\*{successful integration of Genentech, strengthened, innovative capabilities, world’s largest biotech company, leading supplier, cancer medicines}

\*{personalized healthcare, world’s number one supplier, *in vitro* diagnostics, product portfolios, Pharmaceuticals Diagnostics Division}

\*{ability, create, value, stakeholders, future, success, strategy}

--------------------------------------------------------------------------------------------------------------------- Roche 2011

\*{debt crises, Europe, United States, currency markets, slower global economic growth, impact, business landscape}

\*{Increasing pressure, government budgets, healthcare markets}

\*{resources, countries, focus, short-term savings targets, budget controls}

\*{governments, Europe, ease, deficits, impose, price cuts, pharmaceuticals, innovative, patent protected medicines, measures, controlling, reducing, healthcare expenditure}

\*{challenges, strong results}

\*{Group sales, advanced, constant exchange rates, excluding, Tamiflu}

\*{Earnings performance, improved, net income rising}

\*{Dow Jones Sustainability Indexes, Super sector Leader, healthcare, ranking, world’s most sustainable healthcare company}

\*{sustainable corporate policies, practices, create, long-term value, promote, innovation}

\*{support, primary mission, company, prolong, people’s lives, improve, quality of life, excellence, science}

\*{research-based company, developments, healthcare policy, policymakers’ short-term focus, costs, cause}

\*{understand, leading pharmaceutical, diagnostics company, industry, efforts, overcome, current financial, debt crises}

\*{constructive dialogue, aim, contribute, finding, fair and sustainable balance, health policy, industrial policy, balance, rewards, innovation, society, benefit}

\*{healthcare industry, optimistic, medium to long-term outlook, research-based, innovation-driven companies}

\*{fundamental trends, right direction, growing, ageing global population, emerging markets, scientific and technological advances, more targeted, cost-effective treatments, undiminished need, medical progress, diseases, not effectively treated}

\*{increasing economic significance, innovation, nations, regions, communities, compete, investment, jobs}

\*{countries, targeted action, promote, research, innovation}

\*{progress, Shanghai, Beijing, Singapore, cities, emerging markets, global leaders, life sciences, pharmaceuticals, diagnostics}

\*{positive attitude, openness, new scientific discoveries, technologies, definite assets}

\*{countries, research-based healthcare industry’s high productivity, economic growth, generating, skilled jobs, investment, exports}

\*{High expenditures, research and development, strong value creation}

\*{Roche’s R&D activity, headquarters, Switzerland, country’s competitive advantage}

\*{Switzerland, best places, investments, science, strengthen, innovation, promoting, advantages}

\*{optimistic, future}

\*{strategic focus, innovative diagnostics, therapeutics}

\*{world’s biggest biotech company, biopharmaceuticals, market, transform, growing knowledge, disease biology, novel treatments, tests}

\*{research and development, top R&D spenders, industry}

\*{competitors, invest, research and development, areas, competitive advantages, oncology, diabetes, inflammatory, autoimmune diseases, neuroscience}

\*{focus, optimal use, resources, productivity improvements}

\*{world’s leading supplier, cancer medicines, number one *in vitro* diag- nostics company}

\*{combined strengths, pharmaceuticals, diagnostics, proven expertise, molecular biology, company, Personalised Healthcare}

\*{achievements, US launch of Zelboraf, Euro- pean Medicines Agency’s positive opinion, novel treatment, skin cancer, progress, projects, development pipeline}

\*{Cost-effective, targeted medicines, diagnostics, health-care sector’s current difficulties}

\*{pricing pressures, increase, payers, resources, products, services, benefit, patients}

\*{company, focus, develop, medicines, tests, create, real value, patients, physicians, compete successfully, challenging, healthcare market}

\*{strengths, serve}

\*{company’s strong performance, positive outlook, difficult economic, financial environment, Board of Directors, proposing, dividend, increase, non-voting equity security}

\*{approval, Annual General Meeting, consecutive annual dividend, increase}

\*{Board members, election, Annual General Meeting}

\*{re-election, Chairman, confidence}

--------------------------------------------------------------------------------------------------------------------- Roche 2012

\*{Group sales, increased, constant exchange rates, Pharmaceuticals and Diagnostics Divisions, growing faster, markets}

\*{strong growth, United States, emerging markets, Europe, pricing pressure, healthcare budget, cuts}

\*{focus, high­value medicines, diagnostic tests, industry, sales, Europe}

\*{shift, established markets, Europe, grow, emerging market nations, Asia, Latin America, records}

\*{Cancer, cardiovascular disease, leading causes of death, emerging economies, demand, medicines, rising, result}

\*{expand, position, Asia, Latin America, improve, global access to medicines, diagnostics products}

\*{organisational structure, processes, changing market environment}

\*{move, closure of Roche site, Nutley, New Jersey, United States, consolidation of research, early­stage development activities}

\*{Closing, site, not easy decision}

\*{Nutley, company’s success}

\*{Core operating profit, improve, net income, good operating performance, offset, costs, restructuring programmes, tax rate}

\*{core net income, constant exchange rates}

\*{Dow Jones Sustainability Indexes, Roche Supersector Leader, ranking, world’s most sustainable healthcare company}

\*{personalised healthcare}

\*{leader, personalised healthcare, develop, treatments, raise, current standards of care, extend, improve, lives of patients}

\*{projects, pharmaceuticals pipeline, developed, companion diagnostic tests}

\*{strengthened, Personalised Healthcare, launching, cancer medicines, Perjeta, breast cancer, Zelboraf, melanoma, companion diagnostics}

\*{Medical innovation, benefits, patients, partners, healthcare market, payers, economy, society}

\*{Europe, focus, costs, short­term thinking, risk of missing, longer­term opportunities, economy, society}

\*{longer­term perspective tends, neglected, discussions, rising healthcare costs, contribution, pharmaceuticals, diagnostics, medical progress}

\*{Sustainable success, applies, business, long­term thinking, investments}

\*{Innovation, long­term success}

\*{success story, open dialogue, politicians, industry}

\*{propose, dividend}

\*{good results, Board of Directors, propoposing, dividend increase, non­voting equity security}

\*{net income, distributed, shareholders, dividends}

\*{approval, dividend, increase}

\*{members of the Board of Directors, decided, re­election, Board of Directors, Annual General Meeting}

\*{service, contributions, growth, company}

\*{owe, gratitude}

\*{Board of Directors, proposes, election, Roche Group, new member, Board of Directors of Roche Holding Ltd}

\*{Board of Directors, Corporate Executive Committee, promote, growth, company, challenging market environment}

\*{new Corporate Executive Committee, members, recruited, company, former Chief Operating Officer (COO), Diagnostics Division, appointed COO, Pharmaceuticals Division effective}

\*{former Head, Asia, Pacific region, Roche Diagnostics, appointed, new member, Corporate Executive Committee, successor, COO, Diagnostics Division}

\*{newly constituted form, Corporate Executive Committee, progress, Group’s current strategic course, sustainably drive, Roche’s success, global leader, healthcare}

\*{Clinical differentiation, serving patients’ medical needs, better, safer, cost­effective way, cost­sensitive environment}

\*{advance, successful strategy, focus, innovation, benefit of patients, physicians, employees, shareholders}

--------------------------------------------------------------------------------------------------------------------- Roche 2013

\*{excellent performance}

\*{challenging, cost-sensitive environment, focus, targeted medicines, diagnostic tests, expand, strong market position, improve, net income}

\*{strong performance, the Board of Directors, increase, dividend}

\*{strong results}

\*{Group sales, increased, net income, grew}

\*{demand, medicines, diagnostic tests, five new cancer treatments, launched, pipelines, industry}

\*{results, strategy, focusing, innovation, medicines, diagnostics, competitive advantage, developing medically differentiated products}

\*{strengths, targeted, cost-effective treatments, overcoming, today’s healthcare challenges}

\*{developing, improve, prolong , lives, patients, save, resources, healthcare sector}

\*{diagnostic testing, detection, disease, monitoring, treatment modalities, development, targeted treatments, reduce, costs, healthcare system}

\*{strengths, biotech know-how}

\*{expertise, area, opens up, new possibilities, treat, disease, bringing, real medical breakthroughs, patients}

\*{leadership, biotech, result, targeted acquisitions}

\*{Genentech merger, transaction, impact, pharmaceuticals business, diagnostics, market leader, Boehringer Mannheim}

\*{systematic focus, innovation, selective transactions, world’s leading company, oncology, global number one, in vitro diagnostics}

\*{focus, pharmaceuticals, diagnostics, succeed, competitive marketplace}

\*{culture, unique, majority ownership, original founding family, long-term view, pursue, long-term strategy, develop, innovative products}

\*{The Hoffmann and Oeri families, gratitude, support, career}

\*{selection, Dow Jones Sustainability Indices, world’s most sustainable healthcare company, indication}

\*{distinction}

\*{rating, behaving, ethically, responsibly, creating, long-term value, stakeholders}

\*{foundations}

\*{‘the house of Roche is never finished’}

\*{no automatic right, prosperity}

\*{new generation, leaders, Executive Committee, leadership, the Board of Directors, build, business, culture}

\*{chosen, the Annual General Meeting (AGM), step down, Chairman}

\*{pharmaceutical industry, head, Pharmaceuticals Division, CEO, Chairman of the Board}

\*{AGM, the Board of Directors, propose, Christoph Franz, served, non-executive Director, board, Chairman of the Board}

\*{Chairman, personal qualities, record, head, major global company}

\*{experience, exceptional, worldwide, network, assets}

\*{Swiss citizens, voted, referendum, favour, changes, Swiss Constitution, governance regulations, listed companies}

\*{comply, new regulations, propose, changes, company’s Articles of Incorporation, AGM}

\*{Chairman of the Board, members, the Board of Directors, members, Remuneration Committee, elected, shareholders, implement, binding votes, remuneration, mandatory date}

\*{strong, performance, the Board of Directors, proposing, dividend increase, non-voting equity security, dividend increase}

\*{net income, distributed, shareholders, dividends}

\*{shareholders, trust}

\*{the Board, management, employees, accomplished}

--------------------------------------------------------------------------------------------------------------------- Roche 2014

\*{Chairman, the Board of Directors, solid results}

\*{challenging conditions, markets, Europe, delivered, strong sales growth, divisions, strong net income}

\*{successes, research and development}

\*{medicines, improve, treatment, leukemia, pulmonary diseases, skin disorders}

\*{test, detection, virus, cervical cancer}

\*{people, treated, medicines, diagnostic tests, received, diagnosis, targeted, successful treatment}

\*{objective, patients, quality of life, cure, live, longer}

\*{commitment, course, Group, driver, innovation, healthcare sector}

\*{projects, pharmaceutical and diagnostic pipelines}

\*{tackling, diseases, need, bladder cancer, disease, treatment options}

\*{goal, use, cutting-edge science, patients, quality of life, cure, live, longer}

\*{invested, research and development}

\*{potential, modern biosciences, investments}

\*{world’s largest biotech company, use, knowledge, disease biology, develop, new treatments, tests, tailored, specific patient groups, safer, effective}

\*{prevent, global leader, healthcare diagnostics}

\*{early screening, personalised medicines, products, overcome, challenges, healthcare systems}

\*{Innovation}

\*{good ideas, generated}

\*{pharmaceutical products, partnership, biotech firm, university}

\*{global partnership network, alliances, underpinned, targeted acquisition, technologies, active ingredients, expertise}

\*{strategic partnerships}

\*{acquisition, biotech company, InterMune, strengthened, portfolio, respiratory disorders, Esbriet, treatment, fatal lung disease}

\*{Sustainable success, demands, long-term thinking}

\*{achievement, the Group, selection, Dow Jones Sustainability Indices, world’s most sustainable company, life sciences sector}

\*{indicator}

\*{Sustainable success, long-term thinking, commitment}

\*{implementation, development, long-term strategy, benefits, advantage, support, trust, Hoffmann, Oeri families}

\*{strengths}

\*{decentralised management style, strength, foster}

\*{world, employees, company’s key stakeholder groups}

\*{vast differences, national healthcare system, challenges, system}

\*{success, employees, responsibility, latitude, adapt, local situation}

\*{decentralised management style, core strength, foster}

\*{access, innovative tests, medicines, economically weaker countries, challenge, oncology, treatments, complex, demands, facilities, expertise, resources}

\*{local partners, understand, local barriers, patients, improve, preventive screening}

\*{focus, developing, innovative treatments, tests, site expansions}

\*{provide, space, growing workforce, additional research infrastructure, increased production capacities}

\*{investment, Basel headquarters, invest, new, modern research centre, state-of-the-art office building}

\*{increasing, production capacity, China, growing demand, diagnostic tests}

\*{investing, IT hub, Switzerland, modern research laboratories, South San Francisco, expanding, research, production capacities, Germany}

\*{good performance, dividend increase, non-voting equity security}

\*{successful company, excellent prospects}

\*{personal experience, effort, company}

\*{focused, science-driven innovation, cooperative, decentralised structure, Switzerland, world}

\*{sustaining, distinctive culture, future}

\*{addressing, Annual General Meeting (AGM), Roche Holding Ltd, highlight, two important items, agenda}

\*{two prominent figures, wealth, experience, pharmaceutical sector, new Board members}

\*{strong performance, solid outlook, the Board of Directors, proposing, dividend increase, non-voting equity security}

\*{approval, dividend increase}

\*{re-election, existing members, the AGM, changes, the Board of Directors}

\*{Art Levinson, Board of Directors, avoid, potential conflicts, interest, appointment, CEO, research institution}

\*{Art, contributor, Genentech’s success}

\*{leadership, Genentech, biotech companies, world}

\*{the Board of Directors, integration, Genentech}

\*{the Board, contribution, success}

\*{propose, new members, the Board of Directors}

\*{two prominent figures, bring, wealth, experience, pharmaceutical sector, basic biomedical research}

\*{leading, company, positions, President, CEO, Chairman}

\*{Director of the Yale Center for Genome Analysis, award-winning scientist, insights, member, advisory boards, leading pharmaceutical companies}

\*{strategic focus, innovative medicines, diagnostics, growing}

\*{The Board of Directors, Management, world’s most successful research-based healthcare companies}

\*{opportunity, extend, Board of Directors, employees, Corporate Executive Committee, achievements}

\*{shareholders, confidence, company}